Advances in Genetic Variation in Metabolism-related Fatty Liver Disease

Overview

Journal Front Genet

Date 2023 Sep 27

PMID 37753315

Authors

Fan Shi

Mei Zhao

Shudan Zheng

Lihong Zheng

Haiqiang Wang

Affiliations

Soon will be listed here.

Abstract

Metabolism-related fatty liver disease (MAFLD) is the most common form of chronic liver disease in the world. Its pathogenesis is influenced by both environmental and genetic factors. With the upgrading of gene screening methods and the development of human genome project, whole genome scanning has been widely used to screen genes related to MAFLD, and more and more genetic variation factors related to MAFLD susceptibility have been discovered. There are genetic variants that are highly correlated with the occurrence and development of MAFLD, and there are genetic variants that are protective of MAFLD. These genetic variants affect the development of MAFLD by influencing lipid metabolism and insulin resistance. Therefore, in-depth analysis of different mechanisms of genetic variation and targeting of specific genetic variation genes may provide a new idea for the early prediction and diagnosis of diseases and individualized precision therapy, which may be a promising strategy for the treatment of MAFLD.

Citing Articles

MAFLD: Exploring the Systemic Effects Beyond Liver.

Dayal U, Soni U, Bansal S, Aggarwal K, Chennupati C, Kanagala S J Community Hosp Intern Med Perspect. 2025; 15(1):42-48.

PMID: 39867144 PMC: 11759081. DOI: 10.55729/2000-9666.1426.

Reduced Intra- and Extracellular Circulating Postprandial Lysosomal Acid Lipase Activity in Patients with MASLD.

Mischitelli M, Poggiogalle E, Tozzi G, Ferri F, Parisse S, Meloni B Metabolites. 2024; 14(12).

PMID: 39728506 PMC: 11679640. DOI: 10.3390/metabo14120725.

Steatotic liver disease associated with 2,4-dienoyl-CoA reductase 1 deficiency.

Kohlmaier B, Skok K, Lackner C, Haselrieder G, Muller T, Sailer S Int J Obes (Lond). 2024; 48(12):1818-1821.

PMID: 39277655 PMC: 11584395. DOI: 10.1038/s41366-024-01634-z.

Obesity increases genomic instability at DNA repeat-mediated endogenous mutation hotspots.

Kompella P, Wang G, Durrett R, Lai Y, Marin C, Liu Y Nat Commun. 2024; 15(1):6213.

PMID: 39043652 PMC: 11266421. DOI: 10.1038/s41467-024-50006-8.

References

Stefano J, Duarte S, Ribeiro Leite Altikes R, Oliveira C . Non-pharmacological management options for MAFLD: a practical guide. Ther Adv Endocrinol Metab. 2023; 14:20420188231160394. PMC: 10031614. DOI: 10.1177/20420188231160394. View

Xiang H, Wu Z, Wang J, Wu T . Research progress, challenges and perspectives on PNPLA3 and its variants in Liver Diseases. J Cancer. 2021; 12(19):5929-5937. PMC: 8408107. DOI: 10.7150/jca.57951. View

Hirano T . IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2020; 33(3):127-148. PMC: 7799025. DOI: 10.1093/intimm/dxaa078. View

BasuRay S, Wang Y, Smagris E, Cohen J, Hobbs H . Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci U S A. 2019; 116(19):9521-9526. PMC: 6511016. DOI: 10.1073/pnas.1901974116. View

Wang Y, Kory N, BasuRay S, Cohen J, Hobbs H . PNPLA3, CGI-58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice. Hepatology. 2019; 69(6):2427-2441. PMC: 6563103. DOI: 10.1002/hep.30583. View

Banini B, Kumar D, Cazanave S, Seneshaw M, Mirshahi F, Santhekadur P . Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis. Hepatology. 2020; 73(4):1290-1306. PMC: 8046714. DOI: 10.1002/hep.31609. View

Tsai E, Lee T . Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clin Liver Dis. 2017; 22(1):73-92. DOI: 10.1016/j.cld.2017.08.004. View

Bruschi F, Tardelli M, Einwallner E, Claudel T, Trauner M . PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells. Int J Mol Sci. 2020; 21(22). PMC: 7698885. DOI: 10.3390/ijms21228711. View

Liao S, An K, Liu Z, He H, An Z, Su Q . Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China. J Clin Lab Anal. 2022; 36(9):e24626. PMC: 9459258. DOI: 10.1002/jcla.24626. View

10.

Liu W, Zhang X, Li G, Tang L, Zhu P, Rios R . Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. Clin Mol Hepatol. 2021; 28(2):183-195. PMC: 9013609. DOI: 10.3350/cmh.2021.0301. View

11.

Yuan S, Liu H, Yuan D, Xu J, Chen Y, Xu X . PNPLA3 I148M mediates the regulatory effect of NF-kB on inflammation in PA-treated HepG2 cells. J Cell Mol Med. 2019; 24(2):1541-1552. PMC: 6991629. DOI: 10.1111/jcmm.14839. View

12.

Pingitore P, Romeo S . The role of PNPLA3 in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids. 2018; 1864(6):900-906. DOI: 10.1016/j.bbalip.2018.06.018. View

13.

Basu Ray S . PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. Adipocyte. 2019; 8(1):201-208. PMC: 6768214. DOI: 10.1080/21623945.2019.1607423. View

14.

Chen H, Zhang Y, Guo T, Yang F, Mao Y, Li L . Genetic variant rs72613567 of HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han population. Liver Int. 2020; 40(9):2194-2202. PMC: 7496237. DOI: 10.1111/liv.14616. View

15.

Chen L, Xin Y, Geng N, Jiang M, Zhang D, Xuan S . PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis. World J Gastroenterol. 2015; 21(3):794-802. PMC: 4299331. DOI: 10.3748/wjg.v21.i3.794. View

16.

Zhang X, Liu S, Dong Q, Xin Y, Xuan S . The Genetics of Clinical Liver Diseases: Insight into the E167K Variant. J Clin Transl Hepatol. 2018; 6(3):326-331. PMC: 6160302. DOI: 10.14218/JCTH.2018.00022. View

17.

Won Jun D . An analysis of polygenic risk scores for non-alcoholic fatty liver disease. Clin Mol Hepatol. 2021; 27(3):446-447. PMC: 8273633. DOI: 10.3350/cmh.2021.0133. View

18.

Park J, Zhao Y, Zhang F, Zhang S, Kwong A, Zhang Y . IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease. J Hepatol. 2022; 78(1):45-56. PMC: 9772150. DOI: 10.1016/j.jhep.2022.08.022. View

19.

Newberry E, Hall Z, Xie Y, Molitor E, Bayguinov P, Strout G . Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer. Hepatology. 2021; 74(3):1203-1219. PMC: 8390580. DOI: 10.1002/hep.31771. View

20.

Tang S, Zhang J, Mei T, Zhang W, Zheng S, Yu H . Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis. BMC Gastroenterol. 2021; 21(1):490. PMC: 8686634. DOI: 10.1186/s12876-021-02067-y. View